BoneSource

BoneSource

A self-setting, hydroxyapatite (calcium phosphate) cement used in repairing neurosurgical burr holes, contiguous craniotomy cuts and other cranial defects, as well as in the augmentation and restoration of bony contour in the craniofacial skeleton.

BoneSource
• Hardens to form hydroxyapatite and remodels to natural bone by osteoclastic resorption and new bone formation;
• Isothermic during the hardening phase;
• Forms a sculptable calcium phosphate paste with extended working time for contourability;
• Maintains shape and volume over time.

BoneSource

A hydroxyapatite cement/paste used to repair cranial defects
References in periodicals archive ?
Chow, BoneSource hydroxyapatite cement: a novel biomaterial for craniofacial skeletal tissue engineering and reconstruction, J.
Norian SRS (Synthes Corp, Paoli, Pa), BoneSource (Stryker Orthopaedics, Mahwah, NJ), and Callos (Skeletal Kinetics, Cupertino, Calif) are calcium phosphate cements that are mixed in the operating room, injected into poor-quality bone, and cure to develop compressive strength about midway between that of cancellous and cortical bone.
LifeCell Corporation (KCI International), BoneSource TM (Stryker Corporation), Revive TM (Biomerix Corporation), and the Galen VII monitoring device (Galen Medical, LLC.
The Company has initiated the approval process for BoneSource for orthopedic applications in the United States and has commenced studies in Europe.
Its products include the Orthofix external fixation range which is generally less invasive and more cost effective than alternative fixation methods, Spinal Stim( for the enhanced healing of spinal fusions, the Physio-Stim(R) Bone Growth Stimulator for the healing of non-union fractures, the OSCAR( ultrasonic bone cement removal system for hip revision procedures, the A-V Impulse System( for enhancing venous circulation, the Ogden Anchor(R) for anchoring soft tissues to bone, the new Orthofix Intramedullary Nail and Osteogenics BoneSource.
BoneSource, a calcium phosphate-based bone cement, is the first product of its kind to be cleared by the FDA for marketing.
Edgar Wallner, President and CEO of Orthofix International, commented, "We are extremely pleased to receive clearance for these initial indications for BoneSource, a product which we believe holds promise for repairing and replacing bone.
BoneSource HA Cement combines calcium phosphate salts with water, saline or phosphate buffer to produce a bone substitute formulation that converts to hydroxyapatite (HA), a major component of human bone.
Paul Stewart, President of Howmedica Leibinger, stated, "We are pleased about the release of BoneSource because we believe it gives our surgeon customers a useful new tool to improve surgical outcomes, and to reduce operating time by comparison with many grafting procedures.